In a control group, an anti-TGF-β neutralizing antibody was added to the hypoxia-treated glioma supernatants to determine whether ACF impairs glioma TAM M2 polarization by decreasing the hypoxia-induced secretion of TGF-β from glioma cells. The gene discussed is TGFB1; the disease is central nervous system cancer.